NVG 2089
Alternative Names: NVG-2089Latest Information Update: 06 Aug 2025
At a glance
- Originator Nuvig Therapeutics
- Class Anti-inflammatories; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Fc gamma receptor IIB expression stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic inflammatory demyelinating polyradiculoneuropathy; Thrombocytopenia
- Phase I Autoimmune disorders; Myositis
Most Recent Events
- 31 Jul 2025 Phase-II clinical trials in Thrombocytopenia in USA (unspecified route) (NCT07095127)
- 14 May 2025 Phase-II clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (unspecified route)
- 05 Apr 2025 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)